Matthias Bureik

Prof. Matthias Bureik

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2002 in Biochemistry
Verified
Journal Article
Closed access
MBMatthias Bureik
Matthias Bureik
BSBurkhard Schiffler
Burkhard Schiffler
Yasushi HiraokaYasushi Hiraoka
Yasushi Hiraoka
FVFrank Vogel
Frank Vogel
RBRita Bernhardt
Rita Bernhardt

6 January 2002 in Biological Chemistry
Verified
Journal Article
Closed access
MBMatthias Bureik
Matthias Bureik
MLM. Lisurek
M. Lisurek
RBR. Bernhardt
R. Bernhardt
Major advances have been made during the last decade in our understanding of adrenal steroid hormone biosynthesis. Two key players in these pathways are the human mitochondrial cytochrome P450 enzymes CYP11B1 and CYP11B2, which catalyze the final steps in the biosynthesis of cortisol and aldosterone. Using data from mutations found in patients suffering from steroid hormonerelated diseases, from mutagenesis studies and from the construction of threedimensional models of these enzymes, structural information could be deduced that provide a clue to the stereo and regiospecific steroid hydroxylation reactions carried out by these enzymes. In this review, we summarize the current knowledge on the physiological function and the biochemistry of these enzymes. Furthermore, the pharmacological and toxicological importance of these steroid hydroxylases, the means for the identification of their potential inhibitors and possible biotechnological applications are discussed.

1 August 2005 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BDBritta Diesel
Britta Diesel
JRJens Radermacher
Jens Radermacher
MBMatthias Bureik
Matthias Bureik
RBRita Bernhardt
Rita Bernhardt
MSMarkus Seifert
Markus Seifert
EMEckart Meese
Eckart Meese
Purpose: A better understanding of the vitamin D3 metabolism is required to evaluate its potential therapeutic value for cancers. Here, we set out to contribute to the understanding of vitamin D3 metabolism in glioblastoma multiforme. Experimental Design: We did nested touchdown reverse transcription-PCR (RT-PCR) to identify CYP27B1 splice variants and real-time RT-PCR to quantify the expression of CYP27B1. A cell line was treated with calcitriol to determine the effect on the expression of CYP27B1, 1α,25-dihydroxyvitamin D3-24-hydroxylase (CYP24), and vitamin D3 receptor (VDR). We generated three antibodies for the specific detection of CYP27B1 and splice variants. High-performance TLC was done to determine the endogenous CYP27B1 activity and the functionality of CYP27B1 splice variants. Using WST-1 assay, we determined the effect of vitamin D3 metabolites on proliferation. Results: We report a total of 16 splice variants of CYP27B1 in glioblastoma multiforme and a different expression of CYP27B1 and variants between glioblastoma multiforme and normal tissues. We found preliminary evidence for enzymatic activity of endogenous CYP27B1 in glioblastoma multiforme cell cultures but not for the functionality of the splice variants. By adding calcitriol, we found a proliferative effect for some cell lines depending on the dose of calcitriol. The administration of calcitriol led to an elevated expression of CYP27B1 and CYP24 but left the expression of the VDR unaltered. Conclusions: Our findings show that glioblastoma multiforme cell lines metabolize calcidiol. In addition, we show various effects mediated by calcitriol. We found a special vitamin D3 metabolism and mode of action in glioblastoma multiforme that has to be taken into account in future vitamin D3–related therapies.

1 June 2002 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
PEPeter B Ehmer
Peter B Ehmer
MBMatthias Bureik
Matthias Bureik
RBRita Bernhardt
Rita Bernhardt
UMUrsula Müller
Ursula Müller
RHRolf W Hartmann
Rolf W Hartmann

7 October 2010 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
CDCălin-Aurel Drăgan
Călin-Aurel Drăgan
FPFrank T. Peters
Frank T. Peters
PBPierre Bour
Pierre Bour
Andrea Eva SteuerAndrea Eva Steuer
Andrea Eva Steuer
SSStefanie M. Schaan
Stefanie M. Schaan
MBMatthias Bureik
Matthias Bureik

30 April 2005 in FEMS Yeast Research
Verified
Journal Article
Open access
PDF file
CDCălin-Aurel Drăgan
Călin-Aurel Drăgan
SZSilvia Zearo
Silvia Zearo
FHFrank Hannemann
Frank Hannemann
RBRita Bernhardt
Rita Bernhardt
MBMatthias Bureik
Matthias Bureik
Genetically engineered microorganisms are being increasingly used for the industrial production of complicated chemical compounds such as steroids; however, there have been few reports on the use of the fission yeast Schizosaccharomyces pombe for this purpose. We previously have demonstrated that this yeast is a unique host for recombinant expression of human CYP11B2 (aldosterone synthase), and here we report the functional production of human CYP11B1 (steroid 11β-hydroxylase) in S. pombe using our new integration vector pCAD1. In the human adrenal, the mitochondrial cytochrome P450 enzyme CYP11B1 catalyses the conversion of 11-deoxycortisol to cortisol, a key reaction in cortisol biosynthesis that in addition is of fundamental interest for the technical synthesis of glucocorticoids. We observed that the endogenous mitochondrial electron transport system detected previously by us is capable of supplying this enzyme with the reducing equivalents necessary for steroid hydroxylation activity. Under optimised cultivation conditions the transformed yeasts show in vivo the inducible ability to efficiently and reliably convert deoxycortisol to cortisol at an average rate of 201 μM d−1 over a period of 72 h, the highest value published to date for this biotransformation.